Startup raising $3M for drug approach that inhibits tau aggregation in Alzheimer’s disease
Protein misfolding – and resultant tau aggregation – has long been fingered as causative of Alzheimer’s and other neurodegenerative disease. New York startup Oligomerix is addressing this issue with a host of drug development programs under its belt. It’s in the midst of a $3 million round; thus far, according to an SEC filing, $400,000 has been […]